RenovoRx, Inc. (RNXT): Valuation
TTM figures as of June 30, 2026
RenovoRx, Inc. trades at a -15.03% free-cash-flow yield.
Earnings yield -15.47%. Piotroski F-score 4 of 9.
60 month-end valuation observations are on file, starting September 2021.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is RNXT cheap versus its own history?
RenovoRx, Inc. trades at a -15.03% free-cash-flow yield.
What is RNXT's free-cash-flow yield?
RenovoRx, Inc. currently yields -15.03% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.